BIC/FTC/TAF取得长期成功的药理学决定因素：效力、遗传屏障和宽恕。

IF 1.2 4区医学 Q4 MICROBIOLOGY New Microbiologica Pub Date : 2024-12-01

Stefano Bonora

{"title":"BIC/FTC/TAF取得长期成功的药理学决定因素：效力、遗传屏障和宽恕。","authors":"Stefano Bonora","doi":"","DOIUrl":null,"url":null,"abstract":"In the modern ART era, long-term treatment success should be understood as a combination of HIVRNA suppression and a person-centered approach, based on individual therapeutic history, GRT, past toxicities, and comorbidities. The pharmacological determinants of long-term virological suppression are potency, high-genetic barrier, and high-forgiveness regimen. Interplays and relative weights of these three factors can vary according to the different stages of treatment.","PeriodicalId":54723,"journal":{"name":"New Microbiologica","volume":"47 4","pages":"311-313"},"PeriodicalIF":1.2000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Pharmacological determinants of BIC/FTC/TAF to achieve long term success: potency, genetic barrier and forgiveness.\",\"authors\":\"Stefano Bonora\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"In the modern ART era, long-term treatment success should be understood as a combination of HIVRNA suppression and a person-centered approach, based on individual therapeutic history, GRT, past toxicities, and comorbidities. The pharmacological determinants of long-term virological suppression are potency, high-genetic barrier, and high-forgiveness regimen. Interplays and relative weights of these three factors can vary according to the different stages of treatment.\",\"PeriodicalId\":54723,\"journal\":{\"name\":\"New Microbiologica\",\"volume\":\"47 4\",\"pages\":\"311-313\"},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"New Microbiologica\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MICROBIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"New Microbiologica","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MICROBIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

在现代ART时代，长期治疗的成功应该被理解为HIVRNA抑制和以人为本的方法的结合，基于个人治疗史、GRT、过去的毒性和合并症。长期病毒学抑制的药理学决定因素是效力、高遗传屏障和高宽恕方案。这三个因素的相互作用和相对权重可以根据治疗的不同阶段而变化。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Pharmacological determinants of BIC/FTC/TAF to achieve long term success: potency, genetic barrier and forgiveness.

In the modern ART era, long-term treatment success should be understood as a combination of HIVRNA suppression and a person-centered approach, based on individual therapeutic history, GRT, past toxicities, and comorbidities. The pharmacological determinants of long-term virological suppression are potency, high-genetic barrier, and high-forgiveness regimen. Interplays and relative weights of these three factors can vary according to the different stages of treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

New Microbiologica 生物-微生物学

CiteScore

2.20

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： The publication, diffusion and furtherance of research and study on all aspects of basic and clinical Microbiology and related fields are the chief aims of the journal.